|
| 26. |
Munagala, N., Nguyen, S., Lam, W., Lee, J., Joly, A., McMillan, K., and Zhang, W.
(2007)
Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay.
Assay and Drug Development Technologies
5
,
65-73
.
|
| |
Notes:
The authors developed a high-throughput assay in a 1536-well format using the Kinase-Glo® Luminescent Kinase Assay to test for small-molecule ceramide kinase (CERK) inhibitors. The assay was performed using a final compound concentration of 10µM, and an ATP concentration of 5µM in a total volume of 5µl. The assay was robust with Z´-factors of 0.54.
(0003590) |
| |
 |
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 27. |
Baki, A., Bielik, A., Molnár, L., Szendrei, G., and Keserü, G.M.
(2007)
A high throughput luminescent assay for glycogen synthase kinase-3β inhibitors.
Assay and Drug Development Technologies
5
,
75-83
.
|
| |
Notes:
These authors used the Kinase-Glo® Luminescent Kinase Assay to perform a high-throughput screening assay for inhibitors of glycogen synthase kinase-3β in 96-well plates. They used a 1µM ATP concentration and screened 55,000 compounds at 10µM. The assay sensitivity and IC50 values of reference compounds were comparable to radioactive methods; the final optimized assay had an average Z´-factor of 0.72.
(0003591) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 28. |
Polit, J.T. and Kaźmierczak, A.
(2007)
Okadaic acid (1 µM) accelerates S phase and mitosis but inhibits heterochromatin replication and metaphase-anaphase transition in Vicia faba meristem cells
J. Experimental Botany
58
,
2785-2797
.
|
| |
Notes:
The authors of this study investigated the role of okadaic acid (OA), a phosphatase inhibitor, in the regulation of the cell cycle using Vicia faba (fava bean) meristem tissue. They used the Kinase-Glo® Luminescent Kinase Assay to analyze the activity of Histone H1 kinase in OA-treated and untreated meristem. Twenty micromolar histone was used as the substrate and the ATP concentration was 16µM for the assays.
(0003930) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 29. |
Ghosh, S., Lu, Y., Katz, A., Hu, Y., and Li, R.
(2007)
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Am. J. Physiol. Endocrinol. Metab.
292
,
E246-E252
.
|
| |
Notes:
Obesity-associated elevated estrogen increases the risk for breast cancer in postmenopausal women. The rate limiting step in the synthesis of estrogen from androgen is catalyzed by the aromatase enzyme. Normally this enzyme is expressed under a weak promoter in adipose tissue; however in breast cancer a second, strong ovary-specific promoter (PII) drives expression of aromatase. This study investigated the relationship of BRCA1 and aromatase expression. RNA isolated from BRCA-1 siRNA-treated adipose stromal cells was reverse transcribed using the ImProm-II™ Reverse Transcription System. The authors show that siRNA knockdown of BRCA1 resulted in activation of the PII promoter, suggesting that BRCA1 can modulate estrogen biosynthesis in adipose tissue.
(0003606) |
| |
|
| |
Products: ImProm-II™ Reverse Transcriptase | ImProm-II™ Reverse Transcription System |
| 30. |
Lynch, R.A., Etchin, J., Battle, T.E. and Frank, D.A.
(2007)
A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-γ in human cancer cells
Cancer Res.
67
,
1254-1261
.
|
| |
Notes:
STAT1 is a transcription factor that is involved in a variety of cellular processes and behaves like a tumor suppressor in many ways. It is associated with apoptosis, inhibition of cyclin-dependent kinases, and it may mediate the antitumor effects of IFN-γ. The authors of this study designed a bioluminescent reporter assay to identify small molecules that enhance STAT1-dependent gene expression. The bioluminescent assay was performed in 384-well plates using both stably and transiently transfected cell lines. The screening assay was robust, producing a Z´factor value of 0.92, and it identified three compounds that specifically enhanced STAT1-dependent transcriptional activity. Firefly luciferase activity in stable cell lines was assessed using the Bright-Glo® Luciferase Assay System; luciferase activity in the transiently transfected cells was monitored using the Dual-Luciferase® Assay System. Viability of cells in culture was monitored using the CellTiter-Glo® Assay.
(0003732) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | CellTiter-Glo® Luminescent Cell Viability Assay | Dual-Luciferase® Reporter Assay System | pRL-TK Vector |
| 31. |
Fan, F. and Wood, K.V.
(2007)
Bioluminescent assays for high-throughput screening
Assay Drug Dev. Technol.
5
,
127–136
.
|
| |
Notes:
The authors of this paper review bioluminescent assay technologies, discussing HTS reporter, cell-based and luciferase biosensor assays. They divide luminescent assays into three basic categories: assays that measure ATP concentration (cell viability and kinase assays), assays that measure changes in luciferase levels (reporter assays, GPCR assays), and assays that measure changes in luciferin levels (protease [including caspase], P450 and MAO assays).
(0003737) |
| |
|
| |
Products: Renilla Luciferase Assay System | BacTiter-Glo™ Microbial Cell Viability Assay | Bright-Glo™ Luciferase Assay System | Calpain-Glo™ Protease Assay | cAMP-Glo™ Assay | Caspase-Glo® 2 Assay | Caspase-Glo® 3/7 Assay | Caspase-Glo® 6 Assay | Caspase-Glo® 8 Assay | Caspase-Glo® 9 Assay | CellTiter-Glo® Luminescent Cell Viability Assay | Dual-Glo® Luciferase Assay System | Dual-Luciferase® Reporter 1000 Assay System | Dual-Luciferase® Reporter Assay System | Dual-Luciferase® Reporter Assay System 10-Pack | Kinase-Glo® Lumine |
| 32. |
Straszewshi-Chavez, A., Visintin, I.P., Karassina, N., Los, G., Liston, P., Halaban, R., Fadiel, A. and Mor, G.
(2007)
XAF1 mediates tumor necrosis factor-α-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway
Journal of Biological Chemistry
282
,
13059-13072
.
|
| |
Notes:
The authors sought to determine the mechanism by which first-trimester trophoblasts resist FAS ligand-induced apoptosis but remain sensitive to TNFα-mediated apoptosis. First trimester trophoblasts express XAF1 [X-linked inhibitor of apoptosis (XIAP)-associated factor 1], which may be involved in regulating their response to proapoptotic signals. The authors created HaloTag™-XAF1 fusion constructs and transiently transfected the first trimester trophoblast cell line (3A). Cells were labeled with the HaloTag™ TMR ligand, and XAF1 was shown to localize to the cytoplasm. 3A cells transiently transfected with the fusion construct were also separated into cytoplasmic and mitochondrial fractions. The fractions were labeled with HaloTag™ TMR ligand. Expression of the fusion peaked at 48 hours after transfection in both mitochondrial and cytoplasmic fractions. TNFα-treatment of 3A cells induced translocation of endogenous XAF1 to the mitochondria. The authors used the Caspase-Glo® Assays to demonstrate activation of caspase-3 and caspase-9 in response to expression of XAF-1. They also show that caspase-3 activation and XIAP cleavage correlate with translocation of endogenous XAF1 to mitochondria. Viability of 3A and primary trophoblasts over expressing XAF1 was evaluated using the CellTiter® 96 AQueous One-Solution Assay.
(0003760) |
| |
|
| |
Products: Caspase-Glo® 3/7 Assay | Caspase-Glo® 9 Assay | CellTiter 96® AQueous One Solution Cell Proliferation Assay | HaloTag® pHT2 Vector | HaloTag® TMR Ligand |
| 33. |
Kumar, M., Hsiao, K., Vidugiriene, J. and Goueli, S.A.
(2007)
A bioluminescent-based, HTS-compatible assay to monitor G-protein-coupled receptor modulation of cellular cyclic AMP
ASSAY and Drug Development Technologies
5
,
237–245
.
|
| |
Notes:
The authors of this paper introduce a luminescent assay to monitor changes in cellular cAMP concentration. The assay can be used to study the activity of G-protein coupled receptors that modulate adenylate cyclase activity. The assay is compatible with high-throughput screening in 96-, 384- and 1536-well formats.
(0003928) |
| |
|
| |
Products: cAMP-Glo™ Assay |
| 34. |
Galkin, A.V., Melnick, J.S., Kim, S., Hood, T.L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Ding, P., Liu, Y., Sun, F., Schultz, P.G., Gray, N.S. and Warmuth, M.
(2007)
Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK
Proc. Natl. Acad. Sci. USA
104
,
270-275
.
|
| |
Notes:
NVP-TAE684 was identified as an inhibitor of the constitutive anaplastic lymphoma kinase (ALK) activity associated with the NPM-ALK fusion. NPM-ALK fusion protein is created by translocation event characteristic of anaplastic large-cell lymophomas. NVP-TAE684 was screened against a panel of 35 Ba/F3 cell lines expressing a variety of tyrosine kinases constitutively activated by fusion to TEL. The CellTiter-Glo® Luminescent Cell Viability Assay was used to detect any decrease in viability as a result of treatment with NVP-TAE684. The inhibitory effect of NVP-TAE684 was specific for ALK-associated cell proliferation. In a secondary screen to determine potency, TAE684 was screened against two human anaplastic large-cell lymphoma cell lines. Inhibition of proliferation correlated with dosage and was assessed using the Bright-Glo® Luciferase Assay System.
(0003738) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | CellTiter-Glo® Luminescent Cell Viability Assay |
| 35. |
Ma, Y., Katiyar, P., Jones, L.P., Fan, S., Zhang, Y., Furth, P.A., and Rosen, E.M.
(2006)
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Molecular Endocrinology
20
,
14-34
.
|
| |
Notes:
The authors of this study investigate the relationship between BRCA1 and activity of the progesterone receptor (PR) in mammary tumor cells. BRCA1 mutations confer increased risk for steroid hormone-responsive cancers such as endometrial and cervical cancers and prostate cancer. In this study, evidence for interaction between PR and BRCA1 is presented. Glutathione-S-transferase (GST) capture assays were used to determine if PR and BRCA1 interact directly. GST-PR fusion proteins are used to pull down in vitro transcribed and translated BRCA1. In vitro transcription and translation reactions were carried out using a TNT® Rabbit Reticulocyte Lysate system. Interaction between BRCA1 and PR isoforms A and B was observed, and this interaction did not appear to require the presence of progesterone. The authors also showed that BRCA1 regulates expression of several progesterone-responsive genes.
(0003602) |
| |
|
| |
Products: TNT® SP6 Coupled Reticulocyte Lysate System | TNT® SP6 Coupled Reticulocyte Lysate System, Trial Size | TNT® T3 Coupled Reticulocyte Lysate System | TNT® T7 Coupled Reticulocyte Lysate System | TNT® T7 Coupled Reticulocyte Lysate System, Trial Size | TNT® T7 Quick Coupled Transcription/Translation System | TNT® T7 Quick Coupled Transcription/Translation System, Trial Size | TNT® T7/SP6 Coupled Reticulocyte Lysate System | TNT® T7/T3 Coupled Reticulocyte Lysate System |
| 36. |
Yan, W., Suaud, L., Kleyman, R.K., and Rubenstein, R.C.
(2006)
Differential modulation of a polymorphism in the COOH terminus of the α-subunit of the human epithelial sodium channel by protein kinase Cδ.
Am. J. Physiol. Renal Physiol.
290
,
F279-F288
.
|
| |
Notes:
The authors investigated the effect of an A663T polymorphism in the alpha subunit of the human epithelial sodium channel (hENaC) on membrane trafficking. The effect of PKC-mediated phosphorylation on the intracellular trafficking of proteins containing the αT663 or the αA663 polymorphism was investigated. GST and GST-αT663 or GST-αA663 fusion proteins were subjected to in vitro phosphorylation in the presence of the SignaTECT® Assay System buffers. As a positive control for phosphorylation, the SignaTECT® Assay was performed on biotinylated neurogranin(28-43) provided in the SignaTECT® System.
(0003592) |
| |
|
| |
Products: SignaTECT® Protein Kinase C (PKC) Assay System |
| 37. |
Strock, C.J., Park, J.-I., Nakakura, E.K., Bova, G.S., Isaacs, J.T., Bali, D.W., and Nelkin, B.D.
(2006)
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Cancer Research
66
,
7509-7515
.
|
| |
Notes:
The authors investigated the role of cyclin-dependent kinase 5 (CDK5) in motility and invasion of prostate cancer cells. CDK5 kinase activity was measured using the SignaTECT® cdc2 Protein Kinase Assay System. CDK5 was immunoprecipitated from cell lysates from Dunning prostate cancer cells. Expression of a dominant-negative CDK5 mutation in Dunning prostate cancer cells reduced kinase activity and inhibited motility.
(0003594) |
| |
|
| |
Products: SignaTECT® cdc2 Protein Kinase Assay System |
| 38. |
Honegger, K.J., Capuano, P., Winter, C., Bacic, D., Stange, G., Wagner, C.A., Biber, J., Murer, H. and Hernando, N.
(2006)
Regulation of sodium-proton exchanger isoform 3 (NHE3) by PKA and exchange protein directly activated by cAMP (EPAC).
Proc. Natl. Acad. Sci. U S A
103
,
803-808
.
|
| |
Notes:
The SignaTECT® cAMP-Dependent Protein Kinase (PKA) Assay System was used to assess PKA activity in mouse kidney slice homogenates and brush border membrane vesicles.
(0003403) |
| |
|
| |
Products: SignaTECT® cAMP-Dependent Protein Kinase (PKA) Assay System |
| 39. |
Yamada, M., Ikeda, Y., Yano, M., Yoshimura, K., Nishion, S., Aoyama, H., Wang, L., Aoki, H., and Matsuzaki, M.
(2006)
Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy.
FASEB J.
20
,
1197-1199
.
|
| |
Notes:
Type 1 protein phosphatase (PP1) activity is increased in the failing heart. This study investigated the heart disease-related changes in PP1 and PKA activities and investigated whether in vivo delivery of inhibitor-2 would decrease PP1 activity. The SignaTECT® cAMP-Dependent Protein Kinase Assay System was used to assess PP1 and PP2A activity in left ventricular homogenates from normal and UMX7.1 cardiomyopathic hamsters. This assay was also used to assess changes in PP1 activity after adenoviral delivery of inhibitor-2. The authors conclude that PP1 activity contributes to cardiomyopathy during heart failure and that inhibitor-2 can affect PP1 activity in vivo.
(0003489) |
| |
|
| |
Products: SignaTECT® cAMP-Dependent Protein Kinase (PKA) Assay System |
| 40. |
Fasanaro, P., Magenta, A., Zaccagnini, G., Cicchillitti, L., Fucile, S., Eusebi, F., Biglioli, P., Capogrossi, M.C. and Martelli, F.
(2006)
Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress.
FASEB J.
April 7, 2006
,
ePub ahead of print
.
|
| |
Notes:
Human umbilical vein endothelial cells (HUVEC) were resuspended in CaMK extraction buffer and lysed by Dounce homogenization. CaMK activity was measured using the SignaTECT® Calcium/Calmodulin-Dependent Protein Kinase (CaMK II) Assay.
(0003402) |
| |
|
| |
Products: SignaTECT® Calcium/Calmodulin-Dependent Protein Kinase (CaM KII) Assay System |
| 41. |
Tribble, G.D., Mao, S., James, C.E., and Lamont, R.J.
(2006)
A Porphyromonas gingivalis haloacid dehalogenase family phosphatase interacts with human phosphoproteins and is important for invasion.
Proc. Natl. Acad. Sci. U S A
103
,
11027-11032
.
|
| |
Notes:
This study investigated the role of the P. gingivalis haloacid dehalogenase (HAD) family phosphoserine phosphatase SerB563 during invasion of gingival epithelial cells. The Serine/Threonine Phosphatase Assay System was used to assess the activity of wildtype and mutant SerB563.
(0003488) |
| |
|
| |
Products: Serine/Threonine Phosphatase Assay System |
| 42. |
Gil-Bernabé, A.M., Romero, F., Limón-Mortés, M.C., and Tortolero, M.
(2006)
Protein phosphatase 2A stabilizes human securin.
Mol. Cell. Biol.
26
,
4017-4027
.
|
| |
Notes:
This study investigated the regulation of human Securin activity and expression. The Serine/Threonine Phosphatase Assay System was used to determine whether PP2A associated with Securin was active. Human Securin was immunoprecipitated from HCT116 cells and PP2A activity measured. This activity was compared to mock preimmune serum from HCT116 cells. The study found increased PP2A activity in the anti-human Securin cell lysates.
(0003487) |
| |
|
| |
Products: Serine/Threonine Phosphatase Assay System |
| 43. |
Griswold, I., MacPartlin, M., Bumm, T., Goss, V.L., O'Hare, T., Lee, K.A., Corbin, A.S., Stoffregen, E.P., Smith, C., Johnson, K., Moseson, E.M., Wood, L.J., Polakiewicz, R.D., Druker, B.J., and Deininger, M.W.
(2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization irrespective of sensitivity to imatinib.
Mol. Cell. Biol.
26
,
6082-6093
.
|
| |
Notes:
The authors compared the transformation potency of five Bcr-Abl kinase domain mutants. They found reproducible differences in the transformation potency of these five mutants, and they investigated whether these potencies could be explained by changes in kinase activity by performing in vitro kinase assays using a biotinylated peptide substrate. Assays were carried out using varying peptide substrate concentrations. The reactions were stopped, and aliquots of each reaction were transferred to the SAM2® Biotin Capture Membrane. Membranes were dried and phosphate incorporation was determined by scintillation counting.
(0003505) |
| |
|
| |
Products: SAM2® Biotin Capture Membrane |
| 44. |
Thelin, W.R., Kesimer, M., Tarran, R., Kreda, S.M., Grubb, B.R., Sheehan, J.K., Stutts, M. J. and Milgram, S.L.
(2006)
The Cystic Fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A.
J. Biol. Chem.
280
,
41512-41520
.
|
| |
Notes:
This study investigated the role of phosphatases in the deactivation of the Cystic Fibrosis transmembrane conductance regulator (CFTR). CFTR C-terminal peptides were synthesized and immobilized. They were incubated with recombinant PP2A B´ε subunit produced from Rabbit Reticulocyte Lysate or BL21 cells. The recombinant B´ε subunit binds specifically to CFTR-(1451-1476) C-terminal peptide. The core PP2A subunit and A regulatory subunit do not bind to CFTR.
(0003528) |
| |
|
| |
Products: PPase-2A | Rabbit Reticulocyte Lysate System, Nuclease Treated |
| 45. |
Cejas, P.J., Carlson, L.M., Zhang, J., Padmanabhan, S., Kolonias, D., Lindner, I., Haley, S., Boise, L.H. and Lee, K.P.
(2006)
Protein Kinase C βII plays an essential role in dendritic cell differentiation and autoregulates its own expression.
J. Biol. Chem.
280
,
28412-28423
.
|
| |
Notes:
Protein Kinase C activity was assayed in unstimulated KG1, KG1a, KG1a-neo and KG1a-PKC-βII-GFP human leukemic cells using the SignaTECT® Protein Kinase C (PKC) Assay System. For PKC-βII promoter analysis, reporter constructs were cloned into the pGL3-Basic Vector. The pRL-CMV plasmid was used as an internal control to normalize luciferase activity. Reporter assays were carried out using the Dual-Luciferase® Reporter Assay System.
(0003407) |
| |
|
| |
Products: Dual-Luciferase® Reporter Assay System | Dual-Luciferase® Reporter Assay System 10-Pack | pGL3-Basic Vector | SignaTECT® Protein Kinase C (PKC) Assay System |
| 46. |
Harada, C., Nakamura, K., Namekata, K., Okumura, A., Mitamura, Y., Iizuka, Y., Kashiwagi, K., Yoshida, K., Ohno, S., Matsuzawa, A., Tanaka, K., Ichijo, H. and Harada, T.
(2006)
Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo.
American Journal of Pathology
168
,
261-269
.
|
| |
Notes:
The authors of this study investigated the role of apoptosis signal-regulating kinase 1 (ASK1) in neural cell apoptosis during retinal development and ischemic injury. Nucleotides 283 to 713 of the ASK1 cDNA were amplified by PCR and cloned into the pGEM®-T Easy Vector, and sense and antisense probes for in situ hybridization experiments were generated. Anti-ACTIVE® p38 polyclonal antibody was used for immunohistochemistry analyses to investigate the localization of phosphorylated p38 in mouse retina.
(0003530) |
| |
|
| |
Products: Anti-ACTIVE® p38 pAb, Rabbit, (pTGpY) | pGEM®-T Easy Vector System I | pGEM®-T Easy Vector System II |
| 47. |
Stamatovic, S.M., Dimitrijevic, O.B., Keep, R.F., Anjelkovic, A.
(2006)
Protein Kinase Cα-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability.
J. Biol. Chem.
281
,
8379-8388
.
|
| |
Notes:
This study investigated the signaling networks activated by monocyte chemoattractant protein-1 (CCL2) that trigger the redistribution of tight junction proteins of endothelial cells in the blood-brain barrier. The PepTag® Non-Radioactive PKC Assay was used to assess activation of PKC (not isoform-specific) in mouse brain microvascular endothelial cells (mBMEC) total lysates. CCL2 significantly increased activation of PKC in mBMEC.
(0003481) |
| |
|
| |
Products: PepTag® Non-Radioactive PKC Assay |
| 48. |
Su, Q., Wang, S., Balzis, D., Qu, L-K., Wong, A.H-T., and Koromilas, A.
(2006)
Tyrosine phosphorylation acts as a molecular switch to full-scale activation of the eIF2α RNA-dependent protein kinase.
Proc. Natl. Acad. Sci. U S A
103
,
63-68
.
|
| |
Notes:
This study investigated the eukaryotic initiation factor-2 (eIF2) family member Ser/Thr RNA-dependent protein kinase (PKR) to determine whether it is a dual-specificity kinase. The PepTag® Non-Radioactive cAMP-Dependent Kinase Assay was used to determine whether Y69F mutations within the ATP-binding pocket affected ATP-binding and catalytic activity.
(0003483) |
| |
|
| |
Products: PepTag® Non-Radioactive cAMP-Dependent Protein Kinase Assay |
| 49. |
Li, A., Guo, H., Luo, X., Sheng, J., Yang, S., Yin, Y., Zhou, J., and Zhou, J.
(2006)
Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons.
FASEB J.
20
,
1263-1265
.
|
| |
Notes:
Apomorphine (APO) is a D1/D2 dopamine receptor agonist that is used to treat Parkinson disease. This study investigated the effects of APO on fibroblast growth factor-2 (FGF-2) in astrocytes. FGF-2 exhibits strong neuroprotective effects on dopaminergic neurons, which are affected in Parkinson disease. Primary astrocyte culture cells were stimulated with APO or left untreated, and cell lysates were prepared. The cell lysates were tested for PKA activity using the PepTag® Non-Radioactive cAMP-Dependent Protein Kinase Assay. APO was found to increase the phosphorylation levels of PKA through D1 receptors.
(0003482) |
| |
|
| |
Products: PepTag® Non-Radioactive cAMP-Dependent Protein Kinase Assay |
| 50. |
Casas-Flores, S., Rios-Momberg, M., Rosales-Saavedra, T., Martínez-Hernández, Olmedo-Monfil, V., and Herrer-Estrella, A.
(2006)
Cross talk between a fungal blue-light perception system and the cyclic AMP signaling pathway.
Eukaryotic Cell
5
,
499-506
.
|
| |
Notes:
This study investigated the role of the blue-light receptors, BLR-1 and BLR-2, of the fungus Trichoderma atroviride in glucose depletion-induced and light-induced gene expression. Mycelial lysates from dark-grown and light-grown wildtype and BLR mutant T. atroviride strains were assayed for PKA activity using the PepTag® Non-Radioactive cAMP-Dependent Protein Kinase Assay. The results indicate that a BLR-independent mechanism is responsible for inducing PKA activity.
(0003484) |
| |
|
| |
Products: PepTag® Non-Radioactive cAMP-Dependent Protein Kinase Assay |